Skip to main content

CORRECTION article

Front. Med., 05 January 2023
Sec. Dermatology
Volume 9 - 2022 | https://doi.org/10.3389/fmed.2022.1125836

Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis

This article is a correction to:

  1. JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis

    1. Read original article
\nZhanying Hou,&#x;Zhanying Hou1,2†Xuehan Su,&#x;Xuehan Su3,1†Guangming Han&#x;Guangming Han4†Ruzeng XueRuzeng Xue1Yangxia ChenYangxia Chen1Ye ChenYe Chen1Huan WangHuan Wang1Bin YangBin Yang1Yunsheng Liang Yunsheng Liang1*Suyun Ji Suyun Ji1*
  • 1Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China
  • 2Department of Dermatology, Shenzhen Longhua District Central Hospital, Shenzhen, China
  • 3The First School of Clinical Medicine, Southern Medical University, Guangzhou, China
  • 4Department of Rheumatology, Dermatology Hospital, Southern Medical University, Guangzhou, China

A corrigendum on
JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis

by Hou, Z., Su, X., Han, G., Xue, R., Chen, Y., Chen, Y., Wang, H., Yang, B., Liang, Y., and Ji, S. (2022). Front. Med. 9:859330. doi: 10.3389/fmed.2022.859330

In the published article, there was an error regarding the affiliations for author “Xuehan Su.” As well as having the affiliation “Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China,” they should also have “The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: baricitinib, JAK inhibitor, systemic sclerosis, skin fibrosis, digital ulcers

Citation: Hou Z, Su X, Han G, Xue R, Chen Y, Chen Y, Wang H, Yang B, Liang Y and Ji S (2023) Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis. Front. Med. 9:1125836. doi: 10.3389/fmed.2022.1125836

Received: 16 December 2022; Accepted: 20 December 2022;
Published: 05 January 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Hou, Su, Han, Xue, Chen, Chen, Wang, Yang, Liang and Ji. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yunsheng Liang, yes yunshengliang@aliyun.com; Suyun Ji, yes gddhjisuyun@smu.edu.cn

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.